Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice

American Journal of Hematology

Volumn 82, Issue 12, 2007, Pages 1044-1048

  Roszell, Nancy J ^a,b   Danton, Mary Jo ^b   Jiang, Maorong ^a,b   Witte, David ^a   Daugherty, Cynthia ^a   Grimes, Timothy ^b   Girdler, Benjamin ^a,b   Anderson, Kathleen P ^a,b   Franco, Robert S ^c   Degen, Jay L ^b   Joiner, Clinton H ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; PLASMINOGEN;

ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FIBRINOGEN DEFECT; HEMOGLOBIN SC DISEASE; HISTOPATHOLOGY; HYPOXIA; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA; SURVIVAL RATE;

ANEMIA, SICKLE CELL; ANIMALS; FIBRINOGEN; GENE DELETION; GENOTYPE; HEMOGLOBIN, SICKLE; MICE; MICE, TRANSGENIC; PLASMINOGEN; SURVIVAL ANALYSIS;

EID: 36749048642     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20982     Document Type: Article

References (34)

1. Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973;82:44-53.
2. Alkjaersig N, Fletcher A, Joist H, Chaplin H Jr. Hemostatic alterations accompanying sickle cell pain crises. J Lab Clin Med 1976;88:440-449.
3. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol 1998;100:741-749.
4. Richardson SG, Matthews KB, Stuart J, et al. Serial changes in coagulation and viscosity during sickle-cell crisis. Br J Haematol 1979;41:95-103.
5. Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: Evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 1989;19:105-111.
6. Francis RB Jr. Hemostasis. In: Embury SH, Hebbel RB, Mohandas N, Steinberg MH, editors. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994. pp 299-323.
7. Rodgers GM, Hemostatic properties of normal and perturbed vascular cells. FASEB J 1988;2:116-123.
8. Kurantsin-Mills J, Ofosu FA, Safa TK, et al. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992;81:539-544.
9. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: The red cell connection. Blood 2001;98:3228-3233.
10. Francis RB Jr. Protein S deficiency in sickle cell anemia. J Lab Clin Med 1988;111:571-576.
11. Lane PA. Plasma protein C levels in children with sickle cell disease. [comment]. Am J Pediatr Hematol Oncol 1991;13:365-366.
12. Westerman MP, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. [see comment]. J Lab Clin Med 1999;134:352-362.
13. Wun T, Paglieroni T, Tablin F, et al. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997;129:507-516.
14. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. [see comment]. N Engl J Med 1997;337:1584-1590.
15. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683.
16. Franck PF, Bevers EM, Lubin BH, et al. Uncoupling of the membrane skeleton from the lipid bilayer. The cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells. J Clin Invest 1985;75:183-190.
17. Chiu D, Lubin B, Roelofsen B, van Deenen LL. Sickled erythrocytes accelerate clotting in vitro: An effect of abnormal membrane lipid asymmetry. Blood 1981;58:398-401.
18. Trudel M, Garel MC, Saadane N, et al. Towards a mouse model for sickle cell disease: HB SAD. Nouv Rev Fr Hematol 1990;32:407-408.
19. Trudel M, De Paepe ME, Chretien N, et al. Sickle cell disease of transgenic SAD mice. Blood 1994;84:3189-3197.
20. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995;9:2020-2033.
21. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995;9:794-807.
22. Bezerra JA, Bugge TH, Melin-Aldana H, et al. Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver. Proc Natl Acad Sci USA 1999;96:15143-15148.
23. Franco RS, Lohmann J, Silberstein EB, et al. Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J Clin Invest 1998;101:2730-2740.
24. Helley D, Girot R, Guillin MC, Bezeaud A. Sickle cell disease: Relation between procoagulant activity of red blood cells from different phenotypes and in vivo blood coagulation activation. Br J Haematol 1997;99:268-272.
25. Leslie J, Langler D, Serjeant GR, et al. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol 1975;30:159-166.
26. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 2004;11:129-151.
27. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. [see comment]. Science 1997;278:876-878.
28. Hillery C, Foster T, Holzhauer S, et al. Fibrinogen deficiency decreases hepatic infarction in a stem cell transplant model of murine sickle cell disease. Blood 2003;102:81a.
29. Chaplin H Jr, Alkjaersig N, Fletcher AP, et al. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost 1980;43:218-221.
30. Chaplin H Jr, Monroe MC, Malecek AC, et al. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J 1989;66:574-584.
31. Schnog JB, Mac Gillavry MR, Rojer RA, et al. No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. Am J Hematol 2002;71:53-55.
32. Wolters HJ, ten Cate H, Thomas LL, et al. Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: Promises for treatment? Br J Haematol 1995;90:715-717.
33. Adams R. Neurological complications. In: Embury SH, Hebbel RB, Mohandas N, Steinberg MH, editors. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994. pp 599-618.
34. Sherer DM, Dayal AK, Schwartz BM, et al. Extensive spontaneous retroperitoneal hemorrhage: An unusual complication of heparin anticoagulation during pregnancy. J Matern Fetal Med 1999;8:196-199.